IGF1R and cancer: One possible reason for the resistance of cancer cells to IGF-1R inhibitors is the compensatory activation of RTK signaling; therefore, several combination therapies have recently emerged to improve efficacy (104, 105), such as IGF-1R inhibitors in combination with other RTK inhibitors.